BCAN Think Tank session 2: Molecular detection of bladder cancer: The path to progress

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 3, 2010, Pages 334-337

  Robinson, Victoria L ^a   Porter, Michael ^b   Messing, Edward ^c   Fradet, Yves ^d   Kamat, Ashish M ^e   Lotan, Yair ^f  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Urine based markers

Indexed keywords

BLADDER CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SCREENING; CYSTOSCOPY; FALSE POSITIVE RESULT; HEALTH EDUCATION; HEMATURIA; HIGH RISK POPULATION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY;

HUMANS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77951597990     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.07.026     Document Type: Review

References (15)

1. Glas A.S., Roos D., Deutekom M., et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 169 (2003) 1975-1982
2. Budman L.I., Kassouf W., and Steinberg J.R. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2 (2008) 212-221
3. Konety B., and Lotan Y. Urothelial bladder cancer: Biomarkers for detection and screening. BJU Int 102 (2008) 1234-1241
4. Konety B.R. Molecular markers in bladder cancer: A critical appraisal. Urol Oncol 24 (2006) 326-337
5. Zwarthoff E.C. Detection of tumours of the urinary tract in voided urine. Scand J Urol Nephrol Suppl (2008) 147-153
6. National Cancer Institute. Bethesda M: SEER Cancer Statistics Review, 1975-2005 (2008) in Ries LAG MD, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK
7. United States Preventative Services Task Force (USPSTF): Screening for Bladder Cancer in Adults Recommendations Statement (2004), Agency for Healthcare Research and Quality, Rockville, MD
8. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66 (2005) 35-63
9. Hall C., Chang S.S., Dalbagni G., et al. American Urologic Association Bladder Cancer Clinical Guidelines: 2007 Update, Chapter 1: Diagnosis and Treatment Recommendations (2007), American Urological Association Education and Research, Inc, Linthicum, MD
10. Messing E.M., Madeb R., Young T., et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107 (2006) 2173-2179
11. Riley G.F., Potosky A.L., Lubitz J.D., et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33 (1995) 828-841
12. Vrooman O.P., and Witjes J.A. Urinary markers in bladder cancer. Eur Urol 53 (2008) 909-916
13. Johnson E.K., Daignault S., Zhang Y., et al. Patterns of hematuria referral to urologists: Does a gender disparity exist?. Urology 72 (2008) 498-502 Discussion 502-3
14. Yossepowitch O., Herr H.W., and Donat S.M. Use of urinary biomarkers for bladder cancer surveillance: Patient perspectives. J Urol 177 (2007) 1277-1282 Discussion 1282
15. Lotan Y., Svatek R.S., and Sagalowsky A.I. Should we screen for bladder cancer in a high-risk population?. A cost per life-year saved analysis. Cancer 107 (2006) 982-990